Astellas Pharma (OTCMKTS:ALPMY) Hits New 52-Week Low at $9.15

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $9.15 and last traded at $9.34, with a volume of 692432 shares. The stock had previously closed at $9.27.

Astellas Pharma Trading Up 0.7 %

The firm has a market capitalization of $16.90 billion, a P/E ratio of 24.49, a price-to-earnings-growth ratio of 1.23 and a beta of 0.32. The business’s 50-day moving average is $10.79 and its 200 day moving average is $11.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.71.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Monday, February 5th. The company reported $0.12 EPS for the quarter. Astellas Pharma had a net margin of 0.08% and a return on equity of 6.39%. The business had revenue of $2.86 billion for the quarter. As a group, analysts anticipate that Astellas Pharma Inc. will post 0.35 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.